Smith JD, Ludwig ML, Bhangale AD, Brummel C, et al. Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer. Head Neck 2023;45:1281-1287.
PMID: 36932871